Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison.

Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.

Objectives: In this study, the authors evaluated the effectiveness and safety of two of these over a 52-week treatment period.

Methods: A double-center retrospective cohort study was conducted, enrolling patients with moderate to severe psoriasis who received either guselkumab or risankizumab at dermatology clinics for a minimum of 52-weeks.